

## Antibiotic Stewardship for Pediatric UTI

Karen Yeager, DO, MS, FAAP, ABPM-CI

**Division of Emergency Medicine, Clinical Informatics** 

May 14, 2024



#### Karen Yeager, DO, MS, FAAP, ABPM-CI

Associate Program Director | Pediatric Emergency Medicine Fellowship Clinical Informatics Specialist Faculty, Phoenix Children's Hospital | Division of Emergency Medicine Clinical Assistant Professor | University of Arizona College of Medicine – Phoenix Clinical Assistant Professor | Creighton University College of Medicine 1919 E Thomas Rd, Phoenix AZ 85016 <u>kyeager@phoenixchildrens.com</u>



• I have no financial disclosures to report.

PollEv.com/karenyeager534 Send karenyeager534 to 22333

- What percentage of <u>your</u> Urine Dip/UA in office do you estimate result in a positive culture?
  - **A.** < 20%
  - **B.** 20-30%
  - **C.** 30-50%
  - **D.** >50%



- What group has the highest prevalence of urinary tract infection?
  - A. Febrile female 0-3 months of age
  - B. Febrile female 3-6 months of age
  - C. Febrile uncircumcised male 0-3 months of age
  - D. Febrile circumcised male 0-3 months of age
  - E. Febrile female 6-12 months of age

# Objectives



- <u>Recognize</u> benefits and limitations of point of care urine dip/urinalysis to appropriately risk stratify patients for with suspected UTI
- <u>Apply</u> standardized approach for UTI testing and treatment with a lens of antibiotic stewardship
- <u>Evaluate</u> local PCCN opportunities for antibiotic stewardship around UTI evaluation and treatment using evidence-based QI methodology





# <u>Recognize</u>: pros and cons of POC urine testing and UTI epidemiology

#### Recognize

- Urine Culture often obtained for fever without a source or prolonged fever in pediatric patients, particularly in females < 2 years old, or males < 1 year old.
- UA or Udip results determine ED and UC initial antibiotic prescribing practices
  - Pitfalls: bag specimen (overall discourage, but some providers still do), antibiotics prescribed with isolated hematuria or sterile pyuria
    - One study found 94% of pts prescribed antibiotics had pyuria, where as only 55% of those specimens went on to have + urine culture (Watson et al, 2018)
  - Median duration of therapy 7-10 days

#### Recognize

- Hawkins et al, 2023:
  - Antibiotics de-escalated (narrow spectrum based on culture results or discontinued for neg culture) in only 8% of eligible patients from ED
- Watson et al, 2018:
  - Only 55% of ED patients who received antibiotics based on UA/dip results had + urine cultures.
- Forster et al, 2023
  - Of 404 included patients, 389 (96.2%) were discharged on antibiotics and 243 (62.4%) did not have a culture + UTI.
- Poole et al, 2020
  - Successful implementation of a clinical pathway resulted in improved prescribing patterns of antibiotics for UTI (decreased third generation cephalosporin, increased cephalexin)

### Recognize: UTI Epidemiology

- Shaikh et al, 2008 (meta analysis)
  - Among older children (<19 years) with urinary symptoms, the pooled prevalence of UTI (both febrile and afebrile) was 7.8%
  - Among infants presenting with fever, the overall prevalence (95% confidence interval) of UTI was 7.0% (CI: 5.5– 8.4).
- Wrotek et al, 2019:
  - Looked at 459 patients admitted for bronchiolitis, compared to 8k+ control group without bronchiolitis.
  - Frequency of UTI accompanying bronchiolitis was comparable to that in the control group (8.9% vs. 10.9% respectively).

- What group has the highest prevalence of urinary tract infection?
  - A. Febrile female 0-3 months of age <mark>7.5%</mark>
  - B. Febrile female 3-6 months of age <mark>5.7%</mark>
  - C. Febrile uncircumcised male 0-3 months of age 20.1%
  - D. Febrile circumcised male 0-3 months of age <mark>2.4%</mark>
  - E. Febrile female 6-12 months of age <mark>8.3%</mark>

#### **Discussion: Counting the cost**

- Operating costs: high burden of negative UA/Ucx
  - Additional cost if you automatically culture vs. reflex to culture
  - Time for reviewing culture results and responding/communicating with families +/- charting
- Family costs
  - Costs of med they may not need
  - Additional care burden if GI side effects acutely
- Societal costs
  - Increase in antibiotic resistance patterns
    - Pediatrics, 2021: "Pathogens causing UTI are increasingly becoming resistant to commonly used antibiotics, and their indiscriminate use in doubtful cases of UTI must be discouraged"
  - Combatting the antibiotics for everything culture

## <u>Apply</u>: standardized approach for UTI testing and treatment

Ð ( f f f) (f Ð (f  $\theta$ f) f } {



The 5 Ds of Stewardship for UTI	Description	Main Challenge	Successful Intervention Strategies
Diagnosis	Make and document the right diagnosis	Determining which patients have UTI	Clinical decision aids Appropriate collection of cultures Urine procurement by catheterization Reflex urine cultures Computerized decision support systems Selective reporting of urine culture results Text accompanying results to provide interpretation
Drug	Use the right empiric antibiotic	Rising resistance makes empiric treatment challenging	Local susceptibility reports and stratified antibiograms Selective and cascade reporting of antibiotic susceptibility Provider education Computerized decision support systems Post-prescription review by pharmacists Audit and feedback
R Dose	Use the right dose of antibiotic based on site of infection and renal or hepatic dysfunction	Dosage errors are common	Computerized decision support systems Electronic order sets Audit and feedback
Duration	Use antibiotics for the recommended duration	Many studies show a "longer is better" mentality	Computerized decision support systems Electronic order sets Audit and feedback
De-escalation	De-escalate therapy based on susceptibilities and when urine cultures are negative	Labor intensive and occurs too late with UTI to make much impact	Post-prescription review by pharmacists

#### New Literature - Short Course Antibiotics for Febrile UTI

- SCOUT trial (Zaoutis et al, 2022):
  - "In this randomized clinical trial, children assigned to standard-course therapy had lower rates of treatment failure [2 vs. 14 patients] than children assigned to shortcourse therapy. However, the low failure rate of short-course therapy suggests that it could be considered as a reasonable option for children exhibiting clinical improvement after 5 days of antimicrobial treatment"
- G. Montini et al, 2024
  - "RESULTS: From May 2020 through September 2022, 175 children were assessed for eligibility and 142 underwent randomization. The recurrence rate within 30 days of the end of therapy was 2.8% (2/72) in the short group and 14.3% (10/70) in the standard group. The difference between the 2 groups was -11.51% (95% confidence interval, -20.54 to -2.47). The recurrence rate of fUTI within 30 days from the end of therapy was 1.4% (1/72) in the short group and 5.7% (4/70) in the standard group (95% confidence interval, -10.4 to 1.75).
  - CONCLUSIONS: This study demonstrates that a 5-day course is noninferior to a 10day course of oral amoxicillin-clavulanate"



### Example Standardize Approach

- Main TakeAways
  - Judicious use of limited antibiotic duration (rather than 10 days for simple cystitis *without fever*)
  - Limiting UTI evaluation for asymptomatic patients with fever with known source
    - Acute otitis media
    - Croup
    - Strep throat
    - Skin/soft tissue infections

### Apply: clinical guidelines and resources

- UTI Calculator (pitt.edu): https://uticalc.pitt.edu/
- Scenario 1: 7 month old female comes in for sick visit: 24 hours fever tmax 39.5, mild uri symptoms (but is in daycare, that's nothing new). 1 episode of diarrhea but no vomiting. Abd soft, vitally stable in office. No previous history of UTI, but mother concerned because of diarrhea.
  - POC testing
    - A. Yes or
    - B. No
  - Treatment
    - A. Yes or
    - B. No

- Scenario 2: 13 month old uncircumcised male with no previous history of UTI presents with vomiting and fever tmax 38.5 x 2 days. No previous history of UTI, no other symptoms.
  - POC testing
    - A. Yes or
    - B. No
  - Treatment
    - A. Yes or
    - B. No

## Evaluate: Local PCCN Antibiotic Stewardship Opportunities for UTI

6 d  $\theta$ 



#### **Background: Pre-Intervention State**

- EHR inbox is shared by ED APP group and an MA to follow positive culture results (blood, CSF, urine, etc).
  - Mon-Fri business hours MA calls back any cultures that are + and not on appropriate antibiotic therapy.
  - Weekends Daytime APPs do the callbacks
- No mechanism to follow NEGATIVE urine cultures that received antibiotic prescription to discontinue or de-escalate therapy.

### **Pre Intervention**

- Pre-intervention data shows 609 encounters between January-February 2023 were sent home on antibiotics with urine cultures pending.
- 349 (57%) encounters had a negative urine culture and did not meet exclusion criteria.
- 218 (62%) of these encounters were eligible for de-escalation.
- The average length of antibiotic course was 9 days.





Unpublished data

#### Aims

- The primary aim of this QI is to notify 50% of discharged patients prescribed antibiotics for presumed UTI from PCH ED and UC sites who ultimately are found not to have a UTI of negative culture results and instructions to stop antibiotics over a 6 month trial period.
  - Positive UTI defined as: >5 white blood cells per high-power field or dipstick positive for leukocyte esterase) and a positive urine culture (≥50,000 colony-forming units/mL of a uropathogen)
- Secondary aim: The secondary aim of this study is to decrease the average duration of therapy for outpatient treatment of UTI for PCH ED/UC from 9 days to 7.6 days (15% reduction) within 6 months.

#### Interventions

#### Component A

Standardize UTI evaluation and treatment in ED/UC

#### Component B

Data visualization + text message intervention for antibiotic discontinuation

#### Component C

Prospective Survey Study on parental compliance and barriers

### Multidisciplinary Team

- Emergency Medicine
  - Karen Yeager
  - Carol Thrall (NP)
  - Ilyssa Bain (NP)
  - Denise Ortiz (MA)
- Clinical Informatics
  - Vinay Vaidya
  - Mary Kay Walsh
  - Stuart Stough

- Infectious Disease/Antibiotic Stewardship
  - Wassim Ballan
  - Christian Armstrong
- Graduate Medical Education
  - Nisha Isaac
  - Priya Prasher
  - Tatiana Jerome



#### Component B



- Dashboard to isolate eligible ED/UC DC patients + Antibiotic Rx for presumed UTI + Negative final Ucx.
- Daily Email Report to MA/APPs with eligible patients →
  - Patient Name, MRN, Age
  - Acute and Chronic Dx
  - Culture results
  - Link to smart chart
  - Link to send text message
  - Link to smart sheet
  - Text in English/Spanish and reminder of inclusion/exclusion criteria in email

Already on antibiotics in past 72 hours

#### **PDSA Cycles**

- PDSA Cycle 1:
  - Review and adaptation of UTI clinical pathway and ID recommendations for outpatient UTI treatment with Infectious Disease (Dr. Ballan) and Antibiotic Stewardship team March – April 2023
- PDSA Cycle 2:
  - Educational sessions with ED and UC providers, reviewed UTI pathway and prescribing recommendations for simple cystitis/UTI vs. pyelonephritis
  - May 3, 2023 (UC Division Meeting)
  - May 10, 2023 (ED Division Meeting)
- PDSA Cycle 3: Email reminders with updates on progress and reminders
  - April 27, 2023 GO Live Email with UTI pathway reminders and tutorial for dashboard
  - May 31, 2023 Updates on progress from first month and reminders to reinforce education
  - August 4<sup>th</sup>, 2023 Updates on progress from first quarter and reminders to reinforce education.
- PDSA Cycle 4: Adding in Mixed flora
  - Go Live for mixed flora results to dashboard/email June 1, 2023

#### Component C

- Prospective Survey Study
- IRB approved data collection of 47 surveys completed
- Explored parent receipt of text message, compliance with stopping antibiotics and any barriers



uesti	ons	Response Options
1)	Did the patient/patient receive a text message from PCH that child's urine culture is negative and to stop antibiotics	YES     NO
2)	After receiving a text message from our EHR system, did the patient discontinue antibiotics?	<ul><li>YES</li><li>NO</li></ul>
	If the patient did not stop taking antibiotics, why?	<ul> <li>Patient continued to be symptomatic</li> <li>Advised to continue by healthcare provider</li> <li>Patient is/was taking antibiotic for other indication         <ul> <li>Insert other indication</li> </ul> </li> <li>The antibiotics was helping with symptoms</li> <li>Patient did not understand text message instructions</li> <li>Other: (insert reason)</li> </ul>
	How many days of antibiotics were you/your child prescribed	Insert Number
5)	How many days of antibiotics did the patient complete before stopping medication?	Insert number
6) • •	Pain with urination Fever	<ul> <li>Abdominal pain/suprapubic pain</li> <li>Pain with urination</li> <li>Fever</li> <li>Frequent need to urinate</li> <li>Blood with urination</li> </ul>
7)	If the answer to any questions from Questions 4 are yes, has the patient sought medical attention?	YES     NO
		If the answer to Question 6 is yes, please advise patient to seek follow up with Primary Care Provider or return to ED or UC



### Demo Dashboard + Report





Antibiotic Stop/De-escalate



No Action No Text

Clear Filters

No Growth or Mixed Flora (no predominate organism) & On Antibiotics

#### GO LIVE: No Growth on 5/1/2023, Mixed Flora on 5/31/2023

SC	#Uniq Visits	Pt Name	Age at Visit (Yrs)	Admit DT	AcuteDxThisVisit	Extrapolated Result	Culture Result
P	1		3.4	3/9/2024	Acute upper respiratory infection, unspecif	NO GROWTH	NO GROWTH
P	1		5.2	3/8/2024	Constipation _K59.00 // Urinary tract infect	NO GROWTH	NO GROWTH
P	1		5.5	3/8/2024	Constipation _K59.00 // Nonspecific mese	NO GROWTH	NO GROWTH
P	1		3.4	3/8/2024	Urinary tract infection, site not specified	MIXED FLORA	30000 CFU/ML MIXED FLOF
P	1		0.7	3/8/2024	Urinary tract infection, site not specified	NO GROWTH	NO GROWTH
P	1		6.6	3/7/2024	Urinary tract infection, site not specified	MIXED FLORA	50000 CFU/ML MIXED FLOF
P	1		14.6	3/7/2024	Acute pyelonephritis _N10 //	NO GROWTH	NO GROWTH
Total	7						

<

Writer & Dave Saved	(Blank) # Abx Days Saved						
<b>X Writer &amp; Days Saved</b> # Pt Name visits	GenericName	Duration (days)	Days between Abx&Text	Days Saved	RxEntered Date	RequestedBy	^
1	cephalexin	7			3/9/2024	Spontak, Jessica	
1	cephalexin	7			3/9/2024	Brown, Rebecca E	
1	cephalexin	5			3/8/2024	Bowe, Michael	11
1	cephalexin	7			3/8/2024	Huntley, Jennifer	
1	cephalexin	7			3/8/2024	Spontak, Jessica	
7							~

Pt Name, MRN
$\sim$
$\sim \square$

MixedFlora_NoGro	AdmitDate	
Select all	3/3/2024	3/9/2024
(Blank)		
✓ 1		0
✓ 2		
Displays the Perc	entage of De	e-Escalate



#### **Outcome and Process Measures**



 $\bigotimes$ 

**Denominator**: The number of patients **without** a non-UTI infection and a negative urine culture (no growth or MF no significant growth) and a prescription for antibiotics **Numerator**: The number of patients where the Stop/De-Escalate smart sheet was complete or a text was sent to the patient to stop antibiotics



**Denominator**: The number of patients **without** a non-UTI infection and a negative urine culture (no growth or MF no significant growth) and a prescription for antibiotics **Numerator**: The number of patients sent a text message to stop antibiotics





The number of days saved after antibiotics discontinued for negative cultures



**Denominator**: The number of patients with a negative urine culture (no growth or MF no significant growth) **Numerator**: The number of patients with a prescription for antibiotics





**Denominator**: The number of patients with a negative urine culture (no growth or MF no significant growth) and a prescription for antibiotics **Numerator**: The number of patients **with** a non-

UTI infection



Inclusion Criteria/Candidate to Stop Abx: 1) Patient >60 days old; 2) Seen in ED or UC; 3) Negative urine culture; 4) Abx started for UTI (not other indications)

Exclusion Criteria/Do NOT Stop Abx: 1) Patient </= 60 days old; 2) H/O renal ds; 3) Known anatomic abnormalities of urogenital tract except VUR; 4) Presence of indwelling catheters, stents, drains; 5) Severe comorbidity condition such as immunodeficiency, active chemotherapy; 6) Neurogenic bladder; 7) Already on Abx in past 72 hrs; 8) Concern for sexually transmitted infection

Patient Name	Age	Admit Date	Generic Name	Duration Days	Acute Dx This Visit	Chronic Dx	MRN	Culture Result Extrapolated	Culture Result	Abx Stop/De- escalate	Needs Text	SC
	3.4	6/12/2023	sulfamethoxazole- trimethoprim	10	// Vomiting, unspecified _R11.10 //			MIXED FLORA - No Org Predom	40000 CFU/ML METHICILLIN- RESISTANT STAPHYLOCOCCUS AUREUS 20000 CFU/ML MIXED FLORA OBSERVED	<u>Abx Stop/De-</u> <u>escalate</u>	<u>Send</u> Text	<u>SC</u>
	0.3	6/13/2023	cephalexin		// Fever, unspecified _R50.9 // Urinary tract infection, site not specified _N39.0 //		×	NO GROWTH	NO GROWTH	Abx Stop/De- escalate	<u>Send</u> <u>Text</u>	<u>SC</u>
	4.3	6/13/2023	cephalexin		// Urinary tract infection, site not specified _N39.0 //		-	MIXED FLORA - No Org Predom	40000 CFU/ML MIXED FLORA, NO ORGANISM PREDOMINATES. PLEASE SUBMIT NEW SPECIMEN IF CLINICALLY INDICATED.	Abx Stop/De- escalate	<u>Send</u> <u>Text</u>	<u>SC</u>
	0.4	6/13/2023	cephalexin		// Fever, unspecified _R50.9 // Urinary tract infection, site not specified _N39.0 //			NO GROWTH	NO GROWTH	Abx Stop/De- escalate	<u>Send</u> <u>Text</u>	<u>SC</u>

Urine Culture ED/UC Dashboard can be accessed at: Dashboard link

#### Text message prompt to discontinue antibiotics:

Your child's urine test at PCH's Emergency Department/Urgent Care was negative. Child DOB: \*\*/\*\*/\*\*. Please stop antibiotics for urinary tract infection and follow up with your PCP or PCH if your child has painful urination, belly pain, fever and/or vomiting after stopping antibiotics.

El análisis de orina en la sala de emergencia/urgencia de PCH dio negativo. Fecha de nacimiento del niño: \*\*/\*\*/\*\*. Suspenda los antibióticos para infección urinaria y contrólese con el médico si le aparece dolor al orinar, en la panza, fiebre y vómitos luego de suspenderlos.

# Data and Results

ど.

**IF YOU TAKE PROBIOTICS** 

**AND ANTIBIOTICS** 

**DO THEY CANCEL** 

EACH OTHER OUTP

### Primary Aim

- Of all patients with Negative Urine Culture + Antibx Rx (Excluding non-uti dx)
  - > 50% receiving text to stop antibiotics
  - Reasons not to send text: see exclusion criteria





#### Timeline



## • Next Steps:

- Retrospective Analysis of Antibiotic Stewardship Opportunities (2 years) + case-controlled cohort – manuscript drafting underway

- Design/Feasibility manuscript: pending
- Component C: Prospective Survey study: data collected, statistical analysis and manuscript drafting underway

 QI project: Reinforce education, continue monitoring metrics → report out quarterly Potentially a dedicated educational intervention for new hire APPs in ED/UC.





#### Discussion

- What are the local areas for improvement in your practice setting in outpatient UTI diagnosis and management?
  - Diagnosis
  - Drug
  - Dose
  - Duration
  - De-escalation
- Are there other common outpatient infectious conditions that would benefit from similar treatment?

#### Lessons Learned

#### Successes

- Multidisciplinary Team Approach
- Iterative Design Process including end-users
- Divide and Conquer multidirectional approach
- Early and thorough learner engagement
- Quick and frequent communication and check-ins
- Eye towards sustainability early

- Areas for Improvement
  - More thoughtful pre-project planning, particularly for data/metrics reporting and timeline

#### – Start IRBs sooner

- Stay more organized with my notes and milestones (things happening quickly and often)
- Have a plan for scaling back check ins.

#### References

- Watson, Joshua R. MD<sup>\*</sup>; Sánchez, Pablo J. MD<sup>\*</sup>; Spencer, John David MD<sup>\*</sup>; Cohen, Daniel M. MD<sup>\*</sup>; Hains, David S. MD<sup>+</sup>. Urinary Tract Infection and Antimicrobial Stewardship in the Emergency Department. Pediatric Emergency Care 34(2):p 93-95, February 2018. | DOI: 10.1097/PEC.0000000000000688
- Hawkins S, Ericson JE, Gavigan P. Opportunities for Antibiotic Reduction in Pediatric Patients With Urinary Tract Infection After Discharge From the Emergency Department. *Pediatr Emerg Care*. 2023;39(3):184-187. doi:10.1097/PEC.00000000002868
- Goebel MC, Trautner BW, Grigoryan L. The Five Ds of Outpatient Antibiotic Stewardship for Urinary Tract Infections. *Clin Microbiol Rev.* 2021;34(4):e0000320. doi:10.1128/CMR.00003-20
- Forster CS, Almaazi A, Hamdy R, Harik N. Predictors of Empiric Antibiotic Use in the Emergency Department in Children Without Urinary Tract Infections. *Pediatr Emerg Care*. 2022;38(5):e1251-e1256. doi:10.1097/PEC.00000000002586
- Poole NM, Kronman MP, Rutman L, et al. Improving Antibiotic Prescribing for Children With Urinary Tract Infection in Emergency and Urgent Care Settings. *Pediatr Emerg Care*. 2020;36(6):e332-e339. doi:10.1097/PEC.00000000001342
- Kenneth B. Roberts, Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management; Urinary Tract Infection: Clinical Practice Guideline for the Diagnosis and Management of the Initial UTI in Febrile Infants and Children 2 to 24 Months. *Pediatrics* September 2011; 128 (3): 595–610. 10.1542/peds.2011-1330
- Zaoutis T, Shaikh N, Fisher BT, et al. Short-Course Therapy for Urinary Tract Infections in Children: The SCOUT Randomized Clinical Trial. *JAMA Pediatr.* 2023;177(8):782-789. doi:10.1001/jamapediatrics.2023.1979
- Montini G, Tessitore A, Console K, et al. Short Oral Antibiotic Therapy for Pediatric Febrile Urinary Tract Infections: A Randomized Trial. *Pediatrics*. 2024;153(1):e2023062598. doi:10.1542/peds.2023-062598
- Wrotek A, Czajkowska M, Jackowska T. Antibiotic Treatment in Patients with Bronchiolitis. *Adv Exp Med Biol*. 2019;1211:111-119. doi:10.1007/5584\_2019\_391
- Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: a meta-analysis. *Pediatr Infect Dis J*. 2008;27(4):302-308. doi:10.1097/INF.0b013e31815e4122
- Mattoo TK, Shaikh N, Nelson CP. Contemporary Management of Urinary Tract Infection in Children [published correction appears in Pediatrics. 2022 Oct 1;150(4):]. Pediatrics. 2021;147(2):e2020012138. doi:10.1542/peds.2020-012138



#### FACTOR TIP OF THE DAY

### YOU DON'T NEED VANCOMYCIN TO TREAT MSSA

## **Questions?**